Australia vs Belgium: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Australia
94.0%
in 2025
Belgium
94.0%
in 2025
Australia rank
44th
Belgium rank
44th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Australia
- Belgium
How they compare
Australia currently reports 94.0% against 94.0% in Belgium, a difference of 0.0%.
The two have swapped places 3 times across 18 shared years of data; in 2008 it was Australia ahead.
Australia ranks 44th and Belgium ranks 44th of 192 countries.
Australia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Australia | Belgium | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 91.0% | 0.0% | 91.0% | Australia |
| 2010s | 92.7% | 74.9% | 17.8% | Australia |
| 2020s | 95.5% | 94.0% | 1.5% | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Australia or Belgium?
- Australia, at 94.0% against 94.0% in Belgium as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Australia and Belgium?
- 0.0%, with Australia ahead.
- How many years of comparable data are there for Australia and Belgium?
- 18 years are reported by both, from 2008 to 2025.
- How do Australia and Belgium rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Australia ranks 44th and Belgium ranks 44th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.